BioRestorative Therapies Inc is a clinical-stage company that focuses on stem cell-based therapies. This Company announced that the first patient had been enrolled in the Company’s phase 2 clinical trial. This trial evaluates the safety and preliminary efficacy of BRTX-100.
Moreover, the marrow-derived mesenchymal stem cell targets chronic lumbar disc disease. The clinical study is being conducted at up to 15 sites in the United States. The CEO of BioRestorative Therapies added that announcing the first enrolment is the most critical clinical milestone.
Also, our study’s initiation of patient enrollment reinforces the commitment to treating back pain. Also, it provides patients with potentially improved therapeutic options to treat chronic lumbar disc disease. In addition, We are very proud of the BRTX team for its timely execution.
It indeed presents the remarkable accomplishment of the first patient enrolled only six months from our trial initiation and kept us on schedule to meet our strategic targets. Besides this, BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety of the Company.
The Efficacy Of BRTZ-100:
The preliminary efficacy of a single dose intradiscal injection of the Company investigates the autologous stem cell-based therapeutic BRTZ-100. Besides this, a total of 99 eligible patients will be randomized at up to 15 centers in the United States to receive either the investigational drug or control in two ratios in one fashion.
The rapid advancements in regenerating medicine across many musculoskeletal disorders over the last decade remain in many patients who continue to augment their needs and experience of high burden pain and disability.
The primary investigator in the clinical trial added that with the latest problem of BioRestortive, we are looking to see the potential client impact of BRTX-100 to treat the chronic lumbar disc disease that could be a paradigm shift in the treatment of back pain.
About BioRestorative Therapies, Inc:
BioRestorative Therapies Inc explores and develops therapeutic products using cell and tissue protocols. The Company was established in 1997 with its headquarters in the United States. It primarily involves adult stem cells.
Moreover, the Company is holding the common stock under BRTX Stock. Also, the two core programs are related to treating disc/spine disease and metabolic disorders. It includes disc spine orders and a metabolic program.
According to the disc spine program, BRTX-100 is a product formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow. This treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
Besides this, we are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose-derived stem cells to generate brown adipose tissues.
The initial preclinical research indicates that increased brown fat in animals may be responsible for additional caloric burning and reduced glucose and lipid levels.
About BRTX Stock:
OTC Wiki holds detailed information regarding Company’s operation, stock, and all the information. The current price of BRTX Stock is 3.15 US Dollars on August 20, 2022. The quarterly financial analysis of BRTX Stock indicates a net income of 69.23% in June 2021.
The stock prices can have a positive impact on introducing clinical trials. However, the revenues are declined to 11.11% per year over the past five years.
OTC Wiki 
Leave a comment